At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
ALK4290drug
Likely dose
ALK4290 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration (wAMD)
In Brief
A Phase 2 clinical trial evaluating ALK4290 for Wet Age-related Macular Degeneration. Completed, enrolled 26 participants across 5 sites.
Detailed Summary
This study will evaluate the therapeutic effects and safety of 800 mg ALK4290 administered daily over a 6-week dosing period in subjects with refractory wet age-related macular degeneration (wAMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWet Age-related Macular Degeneration
CountriesHungary
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedJun 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedJun 15, 2018
Enrollment StartApr 20, 2018
Primary CompletionNov 29, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.0 years ago
Interventions
ALK4290drug
ALK4290 400 mg tablet twice a day